MorphoSys AG buy FXX
Start price
08.03.21
/
60%
€82.98
Target price
08.03.22
-
Performance (%)
-72.98%
End price
09.03.22
€22.42
Summary
This prediction ended on 09.03.22 with a price of €22.42. The BUY prediction by FXX for MorphoSys AG performed very badly with a performance of -72.98%. FXX has 60% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| MorphoSys AG | 0.820% | 0.820% | 259.840% | -10.776% |
| iShares Core DAX® | -1.785% | -1.250% | 11.664% | 12.714% |
| iShares Nasdaq 100 | -2.154% | 0.300% | 37.531% | 41.653% |
| iShares Nikkei 225® | -4.028% | -3.746% | 17.142% | 0.393% |
| iShares S&P 500 | -1.969% | 0.307% | 25.617% | 40.084% |
According to FXX what are the pros and cons of MorphoSys AG for the foreseeable future?
Pros
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Good rating
Standard Investments for future growth
Valuable balance sheet
Capable Management
Good culture
Leading role in innovation
Some uniques
Growths faster than the competition
Sustainability is important
Small cyclical dependencies
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Fair valuation
High dividend yield expected
positive Cash Flow expected
Normal challenges to pay loans and raise capital
ROE higher than 10% per year
Differentiated customer and product portfolio
Stable Large shareholder and/or long term investor
Medium risks for its business
Top 10 in its market
Known brand
Future proof or reliable business model
Cons
Comments by FXX for this prediction
In the thread Morphosys AG diskutieren
Buy MorphoSys AG
In the thread Trading Morphosys AG
Die von FXX gewählte maximale Laufzeit wurde überschritten